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Key Messages
l	 Retention in the methadone modality exceeded rates reported in 
comparable outcome studies; 79% of the cohort were still receiving 
treatment in the methadone modality at 1-year follow-up.
l	 Participants’ reported use of heroin, methadone (non-prescribed), 
benzodiazepines (non-prescribed), cocaine and crack reduced at  
1-year follow-up. 
l	 The most substantial changes were in opiate consumption; in terms 
of the proportions of participants using the drugs, the frequency of 
use and the average quantities consumed. 
l	 Reductions in reported involvement in acquisitive crime (from 28% 
at treatment intake to 15% at 1-year) and selling/supplying drugs 
(from 22% at treatment intake to 11% at 1-year) were observed.
l	 A decrease in the number of participants who reported injecting 
drug use and in the frequency of injecting drug use was observed 
at 1-year.
l	 Injecting-related risk behaviour was low at treatment intake and 
remained stable over the time period being reported.
l	 Participants’ physical and mental health symptoms remained largely 
unchanged between treatment intake and 1-year follow-up. 
l	 No participants had died in the 1-year follow-up period within this 
modality.
Methadone Modality
The provision of methadone, a long-acting opiate agonist, under 
medical supervision, is the main pharmacological substitution 
intervention for opiate users in Ireland. Initially, a low commencing 
dose (usually between 10-40 mls) is prescribed, aimed at achieving 
a level of comfort while reducing the likelihood of overdose. By the 
end of six weeks of treatment, the individual is usually stabilised on an 
appropriate therapeutic dose. 
Methadone maintenance is a long-term treatment option of no fixed 
duration, usually forming part of a wider process of assisting an 
individual to reduce various forms of drug-related-harm, and to address 
social, legal and financial problems, until the person is ready and willing 
to withdraw from the drug substitution therapy. There are different 
models of maintenance prescribing, ranging from highly structured 
regimes to low-threshold programmes. The ROSIE study methadone 
cohort was recruited from the three main methadone treatment 
settings in Ireland; community-based clinics (22%, n=48), health board 
clinics (50%, n=108) and general practitioners in primary health care 
settings (25%, n=54). In addition, five individuals were recruited from 
the prison setting; however, due to an industrial dispute at the time of 
fieldwork, recruitment within this setting had to be terminated.
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Research Outcome study in Ireland 
(ROsIE)
The Research Outcome Study in Ireland (ROSIE) is the 
first national, prospective, longitudinal, multi-site drug 
treatment outcome study in the country. The National 
Advisory Committee on Drugs (NACD) commissioned 
this research in 2002 as required by the National 
Drugs Strategy Action 99. The aim of the Study is to 
recruit and follow opiate users entering treatment over 
a period of time documenting the changes observed. 
The contract was awarded to Dr Catherine Comiskey 
and NUI Maynooth. 
The ROSIE study follows participants from the point 
of commencing a new treatment episode (treatment 
intake) and monitors progress at time-anchored points; 
6 months, 1-year and 3-years after treatment intake. 
Between September 2003 and July 2004, the ROSIE 
study recruited 404 opiate users on entry into three-index 
treatments; methadone maintenance/reduction (53.2%, 
n=215) structured detoxification (20%, n=81) and 
abstinence-based treatment (20.3%, n=82). In addition, 
a sub-sample of opiate users were recruited from needle-
exchanges (6.4%, n=26).These modalities were part of 
the tender brief from the NACD as they were considered 
to represent the most widely implemented interventions 
for opiate users in Ireland. 
Methadone Cohort: Follow-up Rates
Of the 215 people recruited within the methadone 
modality, 91% (n=196) were located and 78% 
(n=167) successfully completed a 1-year interview. 
Ten individuals withdrew from the study, 19 people 
were located but not successfully interviewed, and 
an additional 19 participants were not located. These 
48 people ‘lost’ to follow-up were excluded from the 
comparative analysis to allow for valid assessment 
across the two time periods. However, it is worth 
noting that 30 of these participants were known 
to be still in their index treatment at 1-year. This is 
the fourth paper in the ROSIE Findings series and it 
provides a snapshot of the outcomes for people in the 
methadone modality one year after treatment intake. 
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MeTHODOLOgy
1. study design
The 404 ROSIE study participants were recruited from both inpatient (hospital, residential programmes & prisons) and outpatient settings 
(community-based clinics, health board clinics & GPs). Participants had to be over 18 years, commencing a new treatment episode, 
prepared to consent to the tracking/follow-up procedures, and willing to provide locator information. Treatment agencies participating in 
the study were purposively (not randomly) sampled to reflect drug treatment in Ireland, and the known geographical spread of provision 
and range of services. In total, 44 agencies providing approximately 54 services located in rural, urban and inner-city areas of Ireland were 
involved in the study. In addition, a Research Advisory Group was established by the NACD to support and monitor the research project. 
Participants were interviewed at the three time periods using a pre-prepared interview schedule which examined key outcome 
measures including
l	 Drug use (drug type, frequency, cost and quantity of drug use)
l	 General health (a 10-point physical & mental health assessment)
l	 Social functioning (employment, accommodation, involvement in crime)
l	 Harm (injecting behaviour & experience of overdose)
l	 Mortality (participant/contact feedback & checking non-followed-up participants against the General Mortality Register).
In addition to a lifetime measure, measures were taken of behaviours in the 90 days preceding interviews, except for injecting-related 
risk behaviour variables when 30 days was used. Individuals were asked about their use of 16 substances. This document focuses 
on the seven most frequently reported problem drugs – referred to as target drugs – (i.e. heroin, methadone (non-prescribed), 
benzodiazepines (non-prescribed), cocaine powder, crack cocaine, cannabis & alcohol) and reports changes in use patterns at 1-year. 
2. Follow-up
Follow-up of participants was assisted by the provision of at least four contacts (locator information) for each person (including a drug 
treatment contact, family member, GP & others). A small remuneration was provided at 1-year follow-up to acknowledge the ongoing 
participation of the individual in the study. 
3. study limitations
1. Although the findings presented here highlight positive outcomes for study participants, they do not indicate a direct causal 
relationship between the treatment received and the outcomes observed.
2. The study did not randomly allocate participants to treatment settings/modality or employ a control group (drug users with similar 
profiles not attending the index treatment).
3. Any individual behaviour change is the result of the interaction of three factors, the person, the environment and the intervention, 
all of which can influence outcomes but could not be controlled for in this study. 
4. Understanding this paper
Data are presented on the 167 individuals recruited within the methadone modality who completed treatment intake and 1-year follow-
up interviews. Only individuals who provided valid answers to each individual question at the two time periods were included in the 
analysis. Missing data were handled by excluding the cases from the particular analysis. Changes in categorical variables were analysed 
using the McNemar test. When the results of these tests were found to be statistically significant1 an asterisk (*) was inserted into the 
frequency tables and/or graphs. Full details of these tests will form part of the ROSIE Study Technical Report on 12-month Outcomes. 
Percentages are rounded up. Comparisons of means were analysed using paired-sample t-tests (‡ indicates statistical significance). 
5. ROsIE Findings series
• ROsIE Findings 1 reported on the 1-year outcomes for the followed-up population (n=305) across all modalities.
• ROsIE Findings 2 presented 1-year outcomes for individuals recruited within the detoxification modality. 
• ROsIE Findings 3 presented 1-year outcomes for participants recruited within the abstinence modality. 
• ROsIE Findings 4 (this document) presents 1-year outcomes for individuals recruited within the methadone modality. 
Further issue-based documents will be published in due course.
1  Statistical significance can only be stated when tests have been carried out on the data to establish the degree of confidence with which we 
can infer that the differences in the observed findings are true and not due to sampling or other error. This is usually reported at a 5% level of 
probability which means where a p value is found to be less than or equal to 0.05 we can be confident that 95 times out of 100 the outcomes and 
differences observed are not due to chance.
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Profile of Participants at Treatment Intake
The demographic characteristics of participants (n=215) in the 
methadone modality are presented in Table 1. The treatment 
entrants were typically male, on average 28 years-of-age, and 
primarily reliant on social welfare payments. The majority of the 
cohort (64%) were parents of children under 18 years-of-age. 
Three-fifths of participants had spent some time in prison and 17% 
were homeless in the 90 days prior to treatment intake interview. 
Table 1 Demographic profile of participants at 
treatment intake
Gender (% male) 68
Average age (yrs) 28
a Early school leavers (%) 43
b Main source of income (%)
  Social welfare 81
  Employed 19
b Homeless (%) 17
Ever in prison (%) 60
Parents (%) 64
a Defined as leaving school before 16 years, or before completion of 
three years of post-primary education (Education, Welfare Act 2000)
b In the 90 days prior to interview at treatment intake
Treatment Retention
Methadone is a long-term treatment option. Figure 1 shows 
that retention in this modality was high; 79% (n=132) of the 
followed-up cohort were still receiving methadone treatment at 
1-year. The vast majority of these 132 individuals continued to 
receive treatment in their index treatment setting (n=106); the 
remaining 26 people transferred to another methadone setting 
within the follow-up period, without a break in treatment. 
Twelve per cent of participants dropped out of methadone 
treatment during the follow-up period; an additional 3% reported 
that they completed their methadone treatment, and 6% 
transferred to another treatment modality.
Figure 1 Treatment Outcome at 1-year
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6% (n=10)
Dropped out 
of treatment 
12% (n=20)
Completed
treatment,
3% (n=5)
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methadone
modality, 
79% (n=132)
Treatment status at 1-year
One year after treatment intake 90% (n=151) of participants 
reported being in some form of drug treatment. The majority of 
the cohort was in methadone treatment (84%). As indicated 
previously, in most cases (132/141) these individuals’ had 
been in continuous methadone treatment over the 1-year 
period. At 1-year follow-up interview, two participants were in a 
structured detoxification programme and none were in residential 
rehabilitation. Twenty-six per cent of the cohort reported attending 
one-to-one counselling and 15% were in group work; this 
category includes Narcotics Anonymous (NA) meetings, aftercare 
programmes, and Community Employment Schemes.
Table 2 Treatment category at 1-year interview
a Treatment at 1-year % n
Currently in Treatment 90 151
Methadone maintenance/reduction 84 141
Detoxification programme 1 2
Residential rehabilitation 0 0
One-to-one counselling 26 44
Group Work 15 25
a Percentages do not sum to 100, as categories are not mutually 
exclusive
Drug Use Outcomes
The number of people who reported using heroin, methadone 
(non-prescribed), benzodiazepines (non-prescribed), cocaine 
powder and crack cocaine in the 90 days prior to interview 
decreased between treatment intake and 1-year follow-up 
(See Table 3). Polydrug use in the 90 days prior to interview 
also reduced; from 78% (n=131) at treatment intake to 56% 
(n=94) at 1-year. The average number of days in which heroin, 
methadone (non-prescribed) and benzodiazepines (non-
prescribed) were used in the 90 days prior to interview reduced. 
Non-significant reductions were observed in the frequency of use 
of the other target drugs, as indicated by changes in mean days 
used (Table 3). In addition, the consumption levels of heroin, 
methadone (non-prescribed) and cocaine decreased over the 
time period, as indicated by changes in the mean daily quantity 
used in the 90 days prior to interview. 
The most substantial changes in drug use over the follow-up 
time period was in individuals’ opiate consumption (i.e. heroin 
and non-prescribed methadone); in terms of the proportions of 
participants using the drugs, the frequency of use and mean daily 
quantities consumed. It is worth noting that at 1-year follow-up 
16% (n=27) of participants reported that they had not used any 
illicit drugs (excluding alcohol) in the 90 days prior to interview. 
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Table 3 Drug use in the 90 days prior to treatment intake & 1-year interview
% Used Mean days used Mean daily quantity used
Intake 1-year Intake 1-year Intake 1-year
% n % n Mean sd Mean sd Mean sd Mean sd
Heroin (grams) 84 139 53 88* 49.8 35.9 15.4 27.6‡ 1.0 1.0 0.3 0.7‡
a Methadone (mls) 48 80 16 26* 15.9 26.6 3.8 15.0‡ 31.5 44.1 9.5 33.9‡
a Benzodiazepines (mgs) 44 72 26 43* 17.6 32.9 7.1 18.3‡ 35.6 93.4 22.7 87.1
Cocaine (grams) 40 66 22 37* 4.8 12.8 3.7 14.0 0.8 2.6 0.3 1.1‡
Crack cocaine 16 26 7 12* 2.6 11.6 1.2 7.9 nc nc nc nc
Cannabis (joints) 67 104 63 98 43.8 41.8 37.8 40.6 5.4 11.7 5.7 16.4
Alcohol (units) 55 84 54 82 12.1 22.4 11.8 23.5 7.0 9.0 6.8 11.1
* McNemar test revealed statistically significant changes. ‡ Paired t-test showed statistical significance. nc Crack cocaine was excluded from the 
analysis due to the inconsistency in the way data was reported. a Refers to the use of non-prescribed drugs.
average amount spent on each drug
The aforementioned changes in reported drug use were 
accompanied by the following changes in the average amount 
individuals spent (€) on a typical drug using day, on four substances: 
l	 A reduction in the average daily heroin spenda from €115.10 
(sd=155.0) at treatment intake to €35.80 (sd=109.30) at 
1-year
l	 A reduction in the average daily cocaine powder spendb 
from €87.70 (sd=282.70) at treatment intake to €20.70 
(sd=74.30) at 1-year 
l	 A reduction in the average daily crack cocaine spendc 
from €32.50 (sd=103.30) at treatment intake to €10.40 
(sd=42.5) at 1-year 
l	 A (non-significant) reduction in the average daily cannabis 
spendd from €2.10 (sd=4.5) at treatment intake to €2.00 
(sd=5.80) at 1-year 
a Based on a bag of heroin (0.113 grams) costing €20
b Based on 1 gram of cocaine powder costing €110 at intake €66 at 
1-year
c Based on 1 rock costing €50 and/or the cost of cocaine powder as 
above
d Based on 1 ounce of cannabis costing €110 at intake €100 at 1-year 
(cost per joint, 39c at intake 35c at 1-year)
Considering only those who reported the use of each drug at 
intake and 1-year follow up on a typical drug using day, the 
following was observed:
n	 At baseline, half of the respondents using heroin were 
spending more than €88.50 per day, while at 1-year, half of 
the respondents were spending more than €40 per day.
n	 At baseline, half of the respondents using cocaine were 
spending more than €110 per day, while at 1-year, half of the 
respondents were spending more than €66 per day.
n	 At baseline, half of the respondents using crack cocaine 
were spending more than €249.25 per day, while at 1-year, 
half of the respondents were spending more than €161.17 
per day.
n	 At baseline, half of the respondents using cannabis were 
spending more than €3.20 per day, while at 1-year, half of  
the respondents were spending more than €3.09 per day.
Crime Outcomes
There was a reduction in the percentage of participants’ reporting 
involvement in acquisitive crime, from 28% (n=44) at treatment 
intake to 15% (n=23) at 1-year.
The numbers of participants who reported selling/supplying drugs 
in the 90 days prior to interview decreased between treatment 
intake and 1-year (see Table 4). In addition, the proportion of 
participants’ who reported theft from a shop, handling stolen 
goods, and soliciting reduced over this time period.
Overall, a higher proportion of participants reported criminal 
involvement in the 90 days prior to treatment intake interview  
(49%, n=75) compared to 1-year follow-up interview (27%, n=41). 
Table 4 Offending behaviour in the 90 days prior 
to treatment intake & 1-year interview
% committed
Intake 1-year
% n % n
Selling/supplying 22 33 11 17*
Theft from a person 8 12 3 5
Theft from a house/home 5 7 5 8
Theft from a shop etc. 20 30 9 14*
Theft from a vehicle 5 8 4 6
Theft of a vehicle 6 9 3 4
Handling stolen goods 22 33 8 12*
Fraud/forgery/deception 8 12 3 4
Assault 5 7 3 4
Criminal damage 5 8 3 4
Soliciting 6 9 1 1*
Breach of the peace 7 10 2 3
* McNemar test revealed statistically significant changes

Authors: Dr Gemma Cox, Dr Catherine Comiskey and Paul Kelly
April 2007Findings 4 : Summary of 1-year outcomes: Methadone Modality
Risk Behaviour Outcomes
The reduction in participants’ drug use was accompanied by a 
decrease in the numbers who reported injecting drug use. At 
treatment intake 44% (n=73) of the cohort injected a drug in 
the 90 days prior to interview compared with 32% (n=53) at 
1-year. A statistically significant decrease in injecting was reported 
across the three most commonly injected substances; cocaine, 
heroin and benzodiazepines (see Figure 2).
Participants also reported a decrease in the frequency of injecting 
drug use, as indicated by changes in the average number of days 
individuals reported injecting in the 90 days prior to treatment 
intake and 1-year interview. At treatment intake, participants 
reported injecting on average 23.1 days (sd=34.6) out of the 
previous 90, this reduced to 8.5 days (sd=21.1) at 1-year 
follow-up. A non-significant reduction was observed in the 
average number of times per day individuals reported injecting. 
At treatment intake, individuals reported injecting on average 
1.4 times per day (sd=2.2), compared with 0.9 times per day 
(sd=3.1) at 1-year.
There was a (non-significant) reduction in the proportion of 
participants who reported an overdose in the 90 days prior to 
interview, from 8% (n=12) at treatment intake to 6% (n=9) at 
1-year. 
Figure 2 Injecting drug use by drug type in the 90 
days prior to treatment intake & 1-year interview
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There were no (significant) changes in participants’ injecting-
related risk behaviours. At treatment intake, participants reported 
low rates of borrowing, lending, and reusing own injecting 
equipment; and the sharing of injecting paraphernalia (e.g. spoons 
and filters). Slight reductions in the numbers who reported lending 
used injecting equipment, reusing own injecting equipment, and 
sharing injecting paraphernalia were observed (see Table 5).
Table 5 Injecting-related risk behaviour in the 30 
days prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Borrowed used needles/
syringes
3 4 3 4
Lent used needles/syringes 5 7 5 8
Reused own needles/
syringes
15 19 11 14
Used filters/spoons after 
someone
4 6 2 3
Health Outcomes
Few significant improvements in the physical or mental health 
symptoms of the respondents were evident over the time period.
Table 6 shows that the numbers of participants who reported 
nine of the 10 physical health symptoms increased over the time 
period. A significant increase in the proportions reporting one of 
these symptoms, stomach pains, was observed. 
Table 6 Physical health symptoms in the 90 days 
prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Poor appetite 74 110 68 101
Tiredness/fatigue 66 97 67 99
Nausea (feeling sick) 37 55 38 56
Stomach pains 28 41 39 58*
Difficulty breathing 27 40 28 41
Chest pains 18 26 18 27
Joint/bone pains 25 37 29 44
Muscle pains 22 33 25 37
Numbness/tingling 
arms/legs
18 26 23 34
Tremors/shakes 22 31 22 32
* McNemar test revealed statistically significant changes
Table 7 illustrates that there were some changes (although not 
statistically significant) in the proportion of participants reporting 
the range of mental health symptoms over the time period under 
investigation. Reductions were observed in the numbers reporting 
four mental health symptom, feeling tense, feeling worthless, 
feeling lonely, and thoughts of ending life. Conversely, increases 
were observed in the numbers who reported the remaining six 
mental health symptoms. 
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Table 7 Mental health symptoms in the 90 days 
prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Feeling tense 55 76 53 73
Suddenly scared for no reason 25 35 25 36
Feeling fearful 29 40 34 46
Nervous/shaking inside 30 42 33 46
Panic attacks 18 26 24 34
Feeling hopeless about future 53 72 53 73
Feelings of worthlessness 46 63 40 55
No interest in things 52 74 58 82
Feeling lonely 50 69 47 64
Thoughts of ending life 22 30 20 27
service Contact
There was an increase in participants’ contact with three health 
and social care services – GP’s, employment/education services 
and housing/homeless services – from treatment intake to  
1-year (see Table 8). The increase in contact with the latter was 
accompanied by a decrease in reported homelessness in the  
90 days prior to interview (from 17% at treatment intake to 
10% at 1-year). In addition, although not statistically significant, 
participants’ reported a decrease in hospital admissions and 
treatment in A & E departments. 
Table 8 Contact with health & social care services 
in the 90 days prior to treatment intake & 1-year 
interview
% reported
Intake 1-year
% n % n
Stayed overnight in hospital 11 18 8 13
Treated in A & E 17 27 14 22
Seen GP 34 52 46 69*
Out-patient appointment 12 19 14 21
Contact with social services 8 13 10 16
Employment/education services 11 16 31 45*
Social welfare services 25 38 18 28
Housing/homeless services 13 19 29 43*
* McNemar test revealed statistically significant changes
Differences Between Those Interviewed 
at 1-year and Those ‘Lost’ to Follow-up
Less than one-quarter of the cohort (22%, n=48) did not 
complete the 1-year follow-up interview. Analysis was undertaken 
to determine whether there were any differences between those 
interviewed at 1-year and those ‘lost’ to follow-up at treatment 
intake, which may bias the results in the current document.
Table 9 shows the differences (at treatment intake) in key 
variables between the two groups. Participants who were 
interviewed at 1-year were significantly more likely to have been 
on social welfare.
The treatment intake characteristics and problems of participants 
interviewed at 1-year and those ‘lost’ to follow-up were compared 
using a logistic regression of key variables (age, gender, frequency 
of heroin use, quantity of heroin used, frequency of cocaine 
use, number of drugs used, number of days injecting drug use, 
frequency of alcohol use, previous treatment for drug/alcohol 
use, treatment setting). The results showed none of the variables 
had a significant effect on whether participants were interviewed 
at 1-year.
Table 9 Comparison of participant characteristics 
at treatment intake between those ‘lost’ to 1-year 
follow-up and those interviewed
‘Lost’ Interviewed
(n=48) (n=167)
Gender (% male) 77 66
Mean age (yrs) 29.4 28.2
Age left school (yrs) 14.8 15.2
On social welfare (%) 66 85*
Treatment setting 
 Inpatient (%) 10 0
 Outpatient (%) 90 100
Time on waiting list (wks) 12.8 11.1
Rated treatment as very  
important (%)
77 80
Used heroin last 90 days (%) 75 84
Mean days used heroin 38.5 49.8
Used cocaine last 90 days (%) 44 40
Mean days used cocaine 5.6 4.8
Used alcohol last 90 days (%) 50 55
Mean days used alcohol 12.2 12.0
Injected last 90 days (%) 42 44
Still on methadone (%) 62.5 79
* Chi-square test statistically significant
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Conclusion
ROSIE is the first national study to have examined 1-year treatment outcomes for opiate users. The findings presented in 
this document demonstrate that retention in methadone treatment was high, and continued participation in a methadone 
programme substantially reduces individuals’ opiate use, their injecting drug use, and their involvement in acquisitive crime. 
Retention in the methadone modality was higher then in comparable outcome studies. The vast majority of ROSIE 
participants followed up within the methadone modality (79%, n=132) continued to receive methadone treatment. 
Even when we add those lost to follow-up interview, the overall retention rate remains high at 75% (n=162/215). 
Retention rates in NTORS, the UK outcome study, were lower; 56% of individuals recruited within the methadone 
maintenance and 51% within methadone reduction programmes were still in methadone treatment at 1-year (Gossop 
et al., 2000)1. Furthermore, only 18% of the ROSIE participants left methadone treatment over the 1-year follow-up 
(drop out 12%, transferred to other modality 6%) compared with one-third (32.6%, n=156) of the NTORS methadone 
cohort. In the Australian outcome study, ATOS, 44% of those who entered methadone at treatment intake were still 
enrolled in their index treatment at 1-year follow-up (Darke et al., 2005)2. DORIS, the Scottish outcome study reported 
that 51.2% of individuals recruited in the methadone modality were still in their index treatment agency at eight months 
follow-up (Slote Morrison & McKeganey, 2006)3. In addition, a higher rate of retention in the national treatment system 
was observed among the ROSIE methadone cohort at 1-year than in other outcome studies; 90% reported being in 
some form of treatment at 1-year, compared with 72% of the NTORS methadone maintenance group and 70% of the 
methadone reduction group (Gossop et al., 2000)1 and 79% of the ATOS methadone cohort (Teesson et al., 2006)4.
ROSIE drug use outcomes were broadly comparable with other studies. Within the ROSIE study significant reductions in 
the proportions using heroin, non-prescribed methadone, benzodiazepines, cocaine and crack cocaine were observed. 
In addition, the frequency of use of heroin, non-prescribed methadone and benzodiazepines also reduced significantly. 
The NTORS study also found significant reductions in the frequency of use of heroin, non-prescribed methadone, 
benzodiazepines, crack cocaine and cocaine powder among individuals recruited within the methadone modality at  
1-year follow-up (Gossip et al, 2000)1. As in NTORS findings from the ROSIE study indicate less satisfactory reductions 
in alcohol use. Within the ROSIE study there were no significant reductions in the proportions using alcohol, the mean 
amount of alcohol consumed or in the mean number of days alcohol was used. However, the proportions drinking within 
the ROSIE study were lower than those observed in NTORS 54% vs. 63% (Gossop et al., 2000)1.
The ATOS study (Teeson et al., 2006)4 reported a higher heroin abstinence rate at 1-year compared with ROSIE  
(65% vs. 47%). However, their rates related to abstinence in the preceding month, while ROSIE employed longer 
time periods and abstinence rates applied to the 90 days preceding interview. The definition of abstinence varies from 
one study to another. At 1-year, 16% of the ROSIE cohort reported abstinence from all illicit and non-prescribed drugs. 
NTORS rates were somewhat higher, with 24.3% of the methadone maintenance cohort reporting abstinence from all 
illicit drugs at 2-years (Gossop et al., 2001)5. The DORIS study usually refers to abstinence as being abstinence from all 
drugs (including prescribed methadone). McKeganey et al., (2006)6 reported a drug abstinence rate of 3.4% for the 
methadone cohort at 33 months post treatment intake; ROSIE’s comparable abstinence rate was 5% at 1-year.
In terms of the ROSIE participants’ physical and mental health, no significant improvements were observed. Within ATOS 
a health index was computed and authors observed some significant improvements in both the physical and mental 
health of participants (Teesson et al., 2006)4. Similarly with NTORS authors found that improvements in health were only 
observed in certain groups (Gossip et al., 2000)1. However, the authors observed that at 1-year follow-up the health 
status of NTORS’clients was still somewhat problematic.
Methadone is a long-term treatment option; consequently retention in treatment is considered a key outcome at 1-year.  
In this study individuals recruited in the ROSIE methadone modality compared favourably with other international outcome 
studies. Participants’ drug use reduced, as did their injecting behaviour, and involvement in crime. Although improvements 
in physical and mental health were disappointing, results from the ROSIE 3-year follow-up will shed some light on whether 
improvements in this domain are associated with long-term treatment. 
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